KR101967502B1 - 다발성 경화증의 치료를 위한 비오틴의 용도 - Google Patents

다발성 경화증의 치료를 위한 비오틴의 용도 Download PDF

Info

Publication number
KR101967502B1
KR101967502B1 KR1020157004516A KR20157004516A KR101967502B1 KR 101967502 B1 KR101967502 B1 KR 101967502B1 KR 1020157004516 A KR1020157004516 A KR 1020157004516A KR 20157004516 A KR20157004516 A KR 20157004516A KR 101967502 B1 KR101967502 B1 KR 101967502B1
Authority
KR
South Korea
Prior art keywords
biotin
pharmaceutical composition
multiple sclerosis
treatment
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157004516A
Other languages
English (en)
Korean (ko)
Other versions
KR20150042799A (ko
Inventor
프레데릭 세델
Original Assignee
아시스땅스 퍼블리끄-오삐또 드 빠리
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아시스땅스 퍼블리끄-오삐또 드 빠리 filed Critical 아시스땅스 퍼블리끄-오삐또 드 빠리
Publication of KR20150042799A publication Critical patent/KR20150042799A/ko
Application granted granted Critical
Publication of KR101967502B1 publication Critical patent/KR101967502B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157004516A 2012-07-26 2013-04-29 다발성 경화증의 치료를 위한 비오틴의 용도 Expired - Fee Related KR101967502B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FRFR12/57254 2012-07-26
FR1257254A FR2993780B1 (fr) 2012-07-26 2012-07-26 Methode de traitement de la sclerose en plaque
US13/644,615 2012-10-04
US13/644,615 US8835487B2 (en) 2012-07-26 2012-10-04 Method of treating multiple sclerosis
PCT/EP2013/058936 WO2014016003A1 (en) 2012-07-26 2013-04-29 Use of biotin for the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
KR20150042799A KR20150042799A (ko) 2015-04-21
KR101967502B1 true KR101967502B1 (ko) 2019-04-09

Family

ID=47294963

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157004516A Expired - Fee Related KR101967502B1 (ko) 2012-07-26 2013-04-29 다발성 경화증의 치료를 위한 비오틴의 용도

Country Status (25)

Country Link
US (5) US8835487B2 (https=)
EP (2) EP2729143B1 (https=)
JP (1) JP6208235B2 (https=)
KR (1) KR101967502B1 (https=)
CN (2) CN109908140A (https=)
AU (1) AU2013295370B2 (https=)
BR (1) BR112015001562A2 (https=)
CA (1) CA2879434C (https=)
CY (1) CY1116304T1 (https=)
DK (2) DK2729143T3 (https=)
EA (1) EA030478B1 (https=)
ES (3) ES2811074T3 (https=)
FR (1) FR2993780B1 (https=)
HK (1) HK1207583A1 (https=)
HR (1) HRP20150260T1 (https=)
HU (1) HUE024558T2 (https=)
IL (1) IL236790A (https=)
LT (1) LT2857019T (https=)
ME (1) ME02060B (https=)
PL (1) PL2729143T3 (https=)
PT (2) PT2857019T (https=)
RS (1) RS53893B1 (https=)
SI (2) SI2857019T1 (https=)
SM (1) SMT201500057B (https=)
WO (1) WO2014016003A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
US9789092B2 (en) 2013-04-29 2017-10-17 Assistance Publique—Hopitaux de Paris Biotin for use in treating X-linked adrenoleukodystrophy
WO2016129362A1 (ja) * 2015-02-13 2016-08-18 ユニマテック株式会社 含フッ素共重合体およびこれを有効成分とする表面改質剤
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
RU2638803C2 (ru) * 2016-06-09 2017-12-15 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки биотина с замедленным высвобождением и способ их получения
RU2611415C1 (ru) * 2015-11-17 2017-02-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ТЕРАПЕВТИЧЕСКИМ ЭФФЕКТОМ В ОТНОШЕНИИ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ (Варианты)
WO2017086835A1 (ru) * 2015-11-17 2017-05-26 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, обладающая терапевтическим эффектом в отношении демиелинизирующих заболеваний (варианты)
EP3275439A1 (en) 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
GB2568849B (en) * 2016-09-01 2022-08-10 Nutrition 21 Llc Magnesium biotinate compositions and methods of use
RU2639488C1 (ru) * 2017-04-06 2017-12-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" Фармацевтическая композиция, содержащая биотин, и способ ее получения
US20200155510A1 (en) * 2018-11-13 2020-05-21 Jds Therapeutics, Llc Treatment of autoimmune disorders, such as relapsing remitting multiple sclerosis and clinically isolated syndrome with biotin compositions
CN112076310A (zh) * 2019-06-14 2020-12-15 苏州融析生物科技有限公司 一种治疗多发性硬化的药物组合物及其制备
GB2613672A (en) 2019-12-16 2023-06-14 Nutrition 21 Llc Methods of production of aginine-silicate complexes
CA3157712C (en) 2020-01-01 2024-01-23 Jotiram PALKAR Synergistic nutritional compositions for enhancing atp efficiency

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011124571A1 (fr) * 2010-04-06 2011-10-13 Assistance Publique - Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3609165A (en) 1968-07-19 1971-09-28 Research Corp 1,3-diazabicyclo {8 3.1.0{9 {0 hex-3-enes
JPH0995448A (ja) 1995-09-29 1997-04-08 Calpis Food Ind Co Ltd:The 血中ビオチン濃度の増加方法およびビオチン含有飲食品
EP0891719A1 (en) * 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
US5789401A (en) 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
US6664039B1 (en) 1998-10-14 2003-12-16 California Institute Of Technology Methods and compositions for modulating neurodegeneration
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
DE19903241A1 (de) 1999-01-28 2000-08-03 Merck Patent Gmbh Galenische Formulierung
EP1536698A1 (en) 2002-08-23 2005-06-08 DSM IP Assets B.V. Novel nutraceutical compositions comprising biotin
DE60333207D1 (de) 2002-09-30 2010-08-12 Daiichi Sankyo Co Ltd Pantethin enthaltendes teilchenförmiges produkt
DE10341240A1 (de) * 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU2003300167B2 (en) * 2003-12-31 2010-09-16 K-Pax Vitamins, Inc. Nutrient compositions and methods for enhanced effectiveness of the immune system
IL162288A0 (en) * 2004-06-01 2005-11-20 Future Products Man S A Compositions and methods for treating neurodegenerative disorders
BG66011B1 (bg) * 2005-05-25 2010-10-29 Райна Щонова Състав от растителен произход
BR112012015084A2 (pt) 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011124571A1 (fr) * 2010-04-06 2011-10-13 Assistance Publique - Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Acta Neurol Scand 1999: 99: 387-392(1999)

Also Published As

Publication number Publication date
CA2879434A1 (en) 2014-01-30
WO2014016003A1 (en) 2014-01-30
US10201528B2 (en) 2019-02-12
US8835487B2 (en) 2014-09-16
AU2013295370B2 (en) 2017-03-02
SI2729143T1 (sl) 2015-05-29
US20140030331A1 (en) 2014-01-30
US20160324830A1 (en) 2016-11-10
US20190117626A1 (en) 2019-04-25
PT2729143E (pt) 2015-03-16
JP2015522630A (ja) 2015-08-06
US20140348920A1 (en) 2014-11-27
SMT201500057B (it) 2015-05-05
EP2729143B1 (en) 2014-12-31
FR2993780A1 (fr) 2014-01-31
US20190117625A1 (en) 2019-04-25
EP2729143A1 (en) 2014-05-14
US9351961B2 (en) 2016-05-31
ES2532364T3 (es) 2015-03-26
KR20150042799A (ko) 2015-04-21
RS53893B1 (sr) 2015-08-31
CY1116304T1 (el) 2017-02-08
DK2729143T3 (en) 2015-03-23
CN109908140A (zh) 2019-06-21
EP2857019A1 (en) 2015-04-08
IL236790A (en) 2017-09-28
AU2013295370A1 (en) 2015-02-19
CN104602689A (zh) 2015-05-06
HRP20150260T1 (hr) 2015-05-08
FR2993780B1 (fr) 2015-02-13
JP6208235B2 (ja) 2017-10-04
ES2811074T3 (es) 2021-03-10
LT2857019T (lt) 2020-09-10
DK2857019T3 (da) 2020-08-17
CA2879434C (en) 2019-04-23
SI2857019T1 (sl) 2020-10-30
EA201590270A1 (ru) 2015-11-30
ES2626079T3 (es) 2017-07-21
HUE024558T2 (hu) 2016-02-29
ME02060B (me) 2015-05-20
PT2857019T (pt) 2020-07-24
HK1207583A1 (en) 2016-02-05
EA030478B1 (ru) 2018-08-31
EP2857019B1 (en) 2020-05-27
PL2729143T3 (pl) 2015-05-29
BR112015001562A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
KR101967502B1 (ko) 다발성 경화증의 치료를 위한 비오틴의 용도
JP5212849B2 (ja) 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
KR101877587B1 (ko) 다발성 경화증(ms)의 새로운 치료
IL266114B1 (en) Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease
US20240148709A1 (en) Methods of treating eye pain and eye disorders
JP6429401B2 (ja) 変異を有するｉ型コラーゲンの小胞体内過剰蓄積正常化剤
TWI879058B (zh) Pde5抑制劑組合於促進神經突生長之新穎用途
HK40008598A (en) Use of biotin for the treatment of multiple sclerosis
US20190134006A1 (en) Method of treating multiple sclerosis
JP2022517734A (ja) ドンペリドン抗神経変性剤の組み合わせと使用
HK40060568A (en) Domperidone antineurodegenerative combinations and use
WO2011043788A2 (en) Daptomycin for multiple sclerosis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220404

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220404

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000